Division of Trauma & Orthopaedics, Addenbrooke's Hospital, University of Cambridge, Cambridge, CB2 0QQ, UK; University of Catania, Catania, 95123, Italy.
Division of Trauma & Orthopaedics, Addenbrooke's Hospital, University of Cambridge, Cambridge, CB2 0QQ, UK.
Osteoarthritis Cartilage. 2020 May;28(5):708-718. doi: 10.1016/j.joca.2019.09.008. Epub 2019 Oct 18.
To report the most up-to-date evidence on the effects of tumour necrosis factor (TNF)-alpha inhibition on cartilage with a focus on its clinical relevance.
A systematic review was performed by searching PubMed, Embase and Cochrane Library databases. Inclusion criteria were studies of any level of evidence published in peer-reviewed journals reporting clinical or preclinical results written in English. Relative data were extracted and critically analysed. PRISMA guidelines were applied, and risk of bias was assessed as well as the methodological quality of the included studies.
13 studies were included after applying the inclusion and exclusion criteria. Three were in vitro human studies from osteoarthritis (OA) patients. Ten were animal modal studies including two in vitro studies, and eight in vivo studies. TNF-alpha inhibition in in vitro studies was generally reported beneficial due to the improved osteochondral viability, proliferation and chondrogenesis. In addition, TNF-alpha inhibition was noted to be beneficial in promoting the natural repair of osteochondral lesions and has a chondroprotective effect in in vivo studies.
Based on current evidence, TNF might have the potential to interfere with the healing process of chondral and osteochondral defects occurring naturally or in low inflammatory environment after a cartilage repair procedure. Therefore, the use of biological agents to inhibit its action in cartilage repair surgery could be beneficial, and this could translate into a promising therapy that improves the outcome of currently available cartilage procedures.
报告关于肿瘤坏死因子 (TNF)-α 抑制对软骨影响的最新证据,重点关注其临床相关性。
通过检索 PubMed、Embase 和 Cochrane Library 数据库进行系统评价。纳入标准为在同行评议期刊上发表的报告临床或临床前结果的任何证据水平的研究,语言为英语。提取并批判性分析相关数据。应用 PRISMA 指南评估纳入研究的偏倚风险和方法学质量。
应用纳入和排除标准后,共纳入 13 项研究。其中 3 项为来自骨关节炎 (OA) 患者的体外人类研究,10 项为动物模型研究,包括 2 项体外研究和 8 项体内研究。体外研究一般报道 TNF-α 抑制有益,因为它改善了软骨下骨的活力、增殖和软骨生成。此外,TNF-α 抑制被认为有益于促进骨软骨病变的自然修复,并在体内研究中具有软骨保护作用。
基于现有证据,TNF 可能有潜力干扰自然发生或软骨修复术后低炎症环境中软骨和骨软骨缺损的愈合过程。因此,在软骨修复手术中使用生物制剂抑制其作用可能是有益的,这可能转化为一种有前途的治疗方法,改善目前可用的软骨手术的效果。